Department of Oncology, Institute of Clinical Medicine, University of Tromso, Tromso; Department of Oncology, University Hospital of Northern Norway, Tromso.
Institute of Medical Biology, University of Tromso, Tromso; Department of Pathology, University Hospital of Northern Norway, Tromso.
Ann Oncol. 2010 Feb;21(2):223-231. doi: 10.1093/annonc/mdp296. Epub 2009 Jul 23.
Platelet-derived growth factors (PDGFs) and vascular endothelial growth factors and their receptors [platelet-derived growth factor receptors (PDGFRs) and vascular endothelial growth factor receptors (VEGFRs)] are related to both angiogenesis and lymphangiogenesis and are important targets in new cancer treatment strategies. We aimed to study the PDGFs/PDGFRs and correlations with lymph node metastasis (LNM) and investigate the prognostic impact of the co-expression of PDGF-B and VEGFR-3 and its correlation with LNM.
Tumor tissue samples from 335 resected patients with stage I-IIIA non-small-cell lung cancer (NSCLC) were obtained and tissue microarrays were constructed from duplicate cores of tumor cells and tumor-related stroma from each specimen. Immunohistochemistry was used to evaluate the expression of the molecular markers PDGF-A, PDGF-B, PDGF-C, PDGF-D, PDGFR-alpha, PDGFR-beta, VEGFR-3 and D2-40.
There were 232 N0 and 103 N+ patients (76 N1 and 27 N2). In multivariate analyses, high tumor cell PDGF-A expression (P = 0.017) correlated with LNM. Tumor cell co-expression of VEGFR-3 and PDGF-B correlated with nodal metastasis and was an independent indicator of poor prognosis (hazard ratio 4.8, confidence interval 95% 2.80-8.31, P < 0.001).
Tumor cell PDGF-A expression correlates with LNM, and the co-expression of PDGF-B and VEGFR-3 is strongly associated with poor survival in NSCLC patients.
血小板衍生生长因子（PDGFs）和血管内皮生长因子及其受体[血小板衍生生长因子受体（PDGFRs）和血管内皮生长因子受体（VEGFRs）]与血管生成和淋巴管生成有关，是新的癌症治疗策略中的重要靶点。我们旨在研究 PDGFs/PDGFRs 与淋巴结转移（LNM）的相关性，并探讨 PDGF-B 和 VEGFR-3 的共表达及其与 LNM 的相关性的预后影响。
从 335 例 I-IIIA 期非小细胞肺癌（NSCLC）切除患者中获得肿瘤组织样本，并从每个标本的肿瘤细胞和肿瘤相关基质的重复核心构建组织微阵列。免疫组织化学用于评估分子标志物 PDGF-A、PDGF-B、PDGF-C、PDGF-D、PDGFR-α、PDGFR-β、VEGFR-3 和 D2-40 的表达。
有 232 例 N0 和 103 例 N+患者（76 例 N1 和 27 例 N2）。在多变量分析中，高肿瘤细胞 PDGF-A 表达（P = 0.017）与 LNM 相关。肿瘤细胞共表达 VEGFR-3 和 PDGF-B 与淋巴结转移相关，是预后不良的独立指标（危险比 4.8，95%置信区间 2.80-8.31，P < 0.001）。
肿瘤细胞 PDGF-A 表达与 LNM 相关，PDGF-B 和 VEGFR-3 的共表达与 NSCLC 患者的生存不良密切相关。
